Global Non-invasive Prenatal Testing Market 2017-2021
About Non-invasive Prenatal Testing
Non-invasive prenatal screening is performed primarily by ultrasonography and serum testing from maternal plasma. Ultrasonography uses the clear tissue behind the infant’s neck to detect genetic defects. A fetus with abnormalities tends to accumulate more fluid. Hence, more clear space is detected behind the neck, which is an indicative measure. Maternal serum screening is a method that involves blood testing in the first and second trimester of the gestation period where specific chemicals such as pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (HCG) are checked.
Technavio’s analysts forecast the global non-invasive prenatal testing market to grow at a CAGR of 16.86% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global non-invasive prenatal testing market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Non-invasive Prenatal Testing Market 2017-2021
Technavio recognizes the following companies as the key players in the global non-invasive prenatal testing market: BGI Genomics, Illumina, Laboratory Corporation of America Holdings, and Quest Diagnostics.
Other Prominent Vendors in the market are: Agilent Technologies, Berry Genomics, F. Hoffman-La Roche, LifeCodexx, Natera, and PerkinElmer.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increase in acceptance of NIPT. The clinical implementation of NIPT is increasing across the world due to its commercialization and the marketing capabilities of vendors. Within a very short span of time, NIPT has been adopted by physicians across the world. Most physicians include NIPT for routine pregnancy diagnosis.”
According to the report, one driver in the market is advantages of non-invasive methods over invasive methods. The introduction of NIPT in 2011 enabled the safe screening and detection of chromosomal abnormalities in fetuses. Invasive methods of prenatal testing are painful. They could also cause miscarriages. However, advances in genomic sciences and bioinformatic analytical tools have led to the development of NIPT. NIPT reduces the chances of miscarriage, involves less pain, and reduces the number of false-positive results. The fetus is not affected because the fetal DNA used for screening is collected from maternal blood and tested using sequencing.
Further, the report states that one challenge in the market is abortion rate and ethical hurdles. With a rapid increase in prenatal screening using NIPT, there are chances of early fetal abortions. NIPT is widely used to detect genetic defects. However, it is also used to determine the gender of the fetus, which could lead to the termination of pregnancy. Choice about the future of the child, physical and emotional harm to the mother, and societal views are ethical challenges associated with prenatal screening.
BGI Genomics, Illumina, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilent Technologies, Berry Genomics, F. Hoffman-La Roche, LifeCodexx, Natera, and PerkinElmer.